Relmada Therapeutics, Inc.

NASDAQ:RLMD

Biotechnology

Healthcare
$2.86 -0.97%

-$0.06 today

Market cap
$304.61M
Beta
0.39
P/E (TTM)
-9.6
EPS (TTM)
-$0.68
52W Low $0.52High $8.00

Volume 1.86M

Average 1.24M

RLMD Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Relmada Therapeutics, Inc.NASDAQ: RLMD

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $19.05M (cash outflow) rose 8.5% year over year, ahead of the -22.2% change in trailing-twelve-month net income. Sequentially, it fell 4.1% from the prior quarter. Over 3 fiscal years it compounded at -28.5% a year.

Context

  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$31.58M (-45.0%) for the fiscal year ending Dec 2026, a slowdown from the -28.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$19.05M-4.1% QoQ
Last fiscal yearDec 2025
-$57.39M-28.3% YoY
LTMMar 2026
-$58.88M-22.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.5%+69.8%+61.3 pp
1 year-28.3%-45.0%-16.7 pp
3-year CAGR-28.5%-12.6%+15.9 pp
5-year CAGR-21.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(57.39M) USD
Year-over-year change
+28.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How RLMD compares with its peers on the latest reported figures

  • RLMD's LTM Mar 2026 net income of $58.88M is the 8th largest of the 9 companies compared; the peer median is $90.81M.
  • Its year-over-year change of -22.2% is the 8th highest of 9, against a peer median of +1.4%.
  • Over three fiscal years its annual growth of -28.5% compares with a peer median of +18.7%.
RLMD Competitors Peer median
Net Income for RLMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$124.31M -5.5%+25.1%1360.6%
ACETAdicet Bio, Inc.LTM Mar 2026$108.83M -7.2%+18.7%—
IMUXImmunic, Inc.LTM Mar 2026$104.29M +8.2%-6.9%—
CBUSCibus, Inc.LTM Mar 2026$103.27M -65.4%+96.0%2409.4%
FBIOFortress Biotech, Inc.LTM Mar 2026$102.15M +215.2%-46.4%154.4%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$78.34M +28.7%+2.0%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$77.27M -7.7%+35.7%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$58.88M -22.2%-28.5%—
VXRTVaxart, Inc.LTM Mar 2026$37.1M +163.8%—14.5%
Peer median (excluding RLMD) $90.81M+1.4%+18.7%757.5%

Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(125.75M)(157.04M)(98.79M)(79.98M)(57.39M)
Depreciation & Amortization1.26K0000
Deferred Income Tax00000
Stock-Based Compensation40.49M44.19M43.81M30.19M14.96M
Change in Working Capital(7.86M)10.59M3.08M(1.58M)(3.95M)
Accounts Receivables79.46K(426.06K)512.43K00
Inventory00000
Accounts Payables2.85M421.04K(1.76M)624.55K(2.56M)
Other Working Capital(10.79M)10.6M4.32M(2.21M)(1.39M)
Other Non-Cash Items1.25M(1.55M)241.16K(381.66K)586.18K
Operating Cash Flow(91.87M)(103.8M)(51.66M)(51.76M)(45.79M)
Capital Expenditures00(4)00
Acquisitions (Net)00000
Purchases of Investments(222.98M)(47.29M)(90.46M)(12.08M)(83.83M)
Sales of Investments168.86M67.03M140.92M63.64M35.69M
Other Investing Activities00000
Investing Cash Flow(54.12M)19.73M50.45M51.56M(48.14M)
Debt Repayment00000
Common Stock Issued185.31M42.73M0246.75K93.64M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.63M2.29M(98.46K)(287.09K)(73.02K)
Financing Cash Flow187.94M45.02M(98.46K)(40.34K)93.56M
Effect of Forex Changes00000
Net Change in Cash41.95M(39.05M)(1.3M)(234.54K)(360.49K)
Free Cash Flow(91.87M)(103.8M)(51.66M)(51.76M)(45.79M)

Relmada Therapeutics, Inc.

NASDAQ:RLMD

Intrinsic Alpha fair value

Locked

Current Price

$2.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.